Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 R

PETT, SARAH LILIAN; ANDRADE-VILLANUEVA, JAIME; AMIN, JANAKI; MADERO, JUAN SIERRA; LOSSO, MARCELO; SILK, DAVID; BELLOSO, WALDO; CLARK, ANDREW; KELLEHER, ANTHONY; GILL, JOHN; SUGIURA, WATARU; CLARKE, AMANDA; GATELL, JOSE; KAISER, ROLF; RUXRUNGTHAM, KIAT; COOPER, DAVID; WOOLLEY, IAN; EMERY, SEAN; ROCKSTROH, JÜRGEN K.; SALOMON HORACIO; HORBAN, ANDREJZ; PORTEIRO, NORMA; TU, ELISE; HARRIGAN, RICHARD; WOLFF, MARCELO; FISHER, MARTIN; PRAZUCK, THIERRY; ARNAIZ, JUAN ALBERTO; MALLON, PATRICK

CLINICAL INFECTIOUS DISEASES

UNIV CHICAGO PRESS

Año: 2016 vol. 63 p. 122 - 132

1058-4838

BACKGROUND: Alternative combination antiretroviral therapies in virologically suppressed human immunodeficiency virus (HIV)-infected patients experiencing side effects and/or at ongoing risk of important comorbidities from current therapy are needed. Maraviroc (MVC), a chemokine receptor 5 antagonist, is a potential alternative component of therapy in those with R5-tropic virus.METHODS: The Maraviroc Switch Study is a randomized, multicenter, 96-week, open-label switch study in HIV type 1-infected adults with R5-tropic virus, virologically suppressed on a ritonavir-boosted protease inhibitor (PI/r) plus double nucleoside/nucleotide reverse transcriptase inhibitor (2 N(t)RTI) backbone. Participants were randomized 1:2:2 to current combination antiretroviral therapy (control), or replacing the protease inhibitor (MVC + 2 N(t)RTI arm) or the nucleoside reverse transcriptase inhibitor backbone (MVC + PI/r arm) with twice-daily MVC. The primary endpoint was the difference (switch minus control) in proportion with plasma viral load (VL)